Skip to content
Screener

AbCellera Biologics Inc. ABCL Shares issued and restricted stock units ("RSUs") vested under stock option plan

Shares issued and restricted stock units ("RSUs") vested under stock option plan at other companies

Talkspace, Inc. logo
Talkspace, Inc.TALK
-$1.7M-50.7%
Talkspace, Inc. logo
Talkspace, Inc.TALK
-$1.7M-50.7%
MRD
Meridian Holdings, Inc.MRDN
$0-100%
Taboola.com Ltd. logo
Taboola.com Ltd.TBLA
$7.69M+219%
First Busey Corporation logo
First Busey CorporationBUSE
$0
First Busey Corporation logo
First Busey CorporationBUSE
$0

Other financials

Income statement

See full
Revenue$4.1M-76.3%
Operating income-$62.8M-26.6%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$2.1M-84.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$2.12B+112%
Enterprise value$2.11B+108%
P/S32×+1.6×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001703057-26-000046
Line itemCommon Shares / SharesCommon Shares / AmountAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive LossTotal Shareholders'Equity
Foreign currency translation adjustment1,8151,815
Net loss(43,165)(43,165)
Balances as of March 31, 2026303,945,581$816,533$196,616$(72,647)$(2,419)$938,083
Shares issued and restricted stock units (“RSUs”) vested under stock option plan2,524,0514,709(2,898)1,811
Stock-based compensation12,28612,286
Foreign currency translation adjustment(733)(733)
Net loss(55,427)(55,427)
Balances as of June 30, 2026306,469,632$821,242$206,004$(128,074)$(3,152)$896,020

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s shares issued and restricted stock units ("rsus") vested under stock option plan?
AbCellera Biologics Inc. (ABCL) reported shares issued and restricted stock units ("rsus") vested under stock option plan of $1.81M in Q2 2026.
How has AbCellera Biologics Inc.'s shares issued and restricted stock units ("rsus") vested under stock option plan changed year-over-year?
AbCellera Biologics Inc.'s shares issued and restricted stock units ("rsus") vested under stock option plan increased by 2380.8% year-over-year, from $73K to $1.81M.
What is the long-term trend for AbCellera Biologics Inc.'s shares issued and restricted stock units ("rsus") vested under stock option plan?
Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s shares issued and restricted stock units ("rsus") vested under stock option plan has grown at a -28.7% compound annual growth rate (CAGR), from $1.58M to $806K.
What does shares issued and restricted stock units ("rsus") vested under stock option plan mean?
Shares issued and restricted stock units ("RSUs") vested under stock option plan as reported by AbCellera Biologics Inc. Common Shares.

Ask your AI about AbCellera Biologics Inc.'s shares issued and restricted stock units ("rsus") vested under stock option plan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude